China-based WuXi AppTec, a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, reported its small-molecule process development and manufacturing subsidiary, Shanghai SynTheAll Pharmaceutical Co., Ltd., is opening a clinical operations center in San Diego, California.

According to company officials, the center will provide Process R&D and API manufacturing services for early phase clinical studies. “Greater San Diego is one of the most innovative biopharma and biomedical hubs in the world, with more than 1,000 life sciences companies and more than 80 research institutes. WuXi has been serving the San Diego life sciences community since the very beginning with many collaborative partners.”

"STA is a leading global Contract Development and Manufacturing Organization for innovative small molecule active pharmaceutical ingredients and advanced intermediates, from preclinical through commercial," said Dr. Minzhang Chen, CEO of STA. "Our new U.S. based presence with a highly experienced scientific and production team is another step towards better enabling our partners through added capacity, greater flexibility, and our customer-centric approach to drug development and manufacturing services."

"WuXi's open-access capability and technology platform strives to enable anyone and any company to discover and develop healthcare products more efficiently and cost effectively," said Dr. Ge Li, Chairman/CEO of WuXi AppTec. "This new facility further brings our comprehensive R&D services closer to our North American customers and partners in their efforts to improve patients' lives."